ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Eisai Co., Ltd.

Business Summary

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2022 JPYUSD
Gross Profit569,791M5,070.54M
Operating income59,623M530.58M
Income before tax54,458M484.61M
Net income47,954M426.74M
Diluted EPS167.241.48
Dividends Per Share1601.42
Total Assets1,239.31B10,210.62M
Total liabilities467,781M3,854.01M
Total equity748,821M6,169.48M
Operating cash flow117,590M1,046.42M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 600,054M 642,834M 695,621M 645,942M 756,226M
Gross Profit 386,599M 446,436M 510,352M 465,186M 569,791M
Operating income 75,595M 99,921M 138,679M 56,543M 59,623M
Income before tax 76,803M 89,454M 128,063M 52,551M 54,458M
Net income 51,845M 63,386M 121,767M 42,119M 47,954M
EBITDA 101,778M 126,762M 172,379M 92,842M 98,021M
Diluted EPS 180.97 221.11 424.79 146.90 167.24
Dividends Per Share 150 150 160 160 160
Total Assets 1,049.03B 1,071.52B 1,062.14B 1,090.00B 1,239.31B
Total liabilities 434,934M 419,539M 359,509M 362,067M 467,781M
Total equity 593,582M 628,120M 678,127M 703,183M 748,821M
Operating cash flow 149,649M 103,714M 102,782M 73,853M 117,590M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 5,414.06M 5,796.79M 6,397.94M 6,090.49M 6,729.62M
Gross Profit 3,488.14M 4,025.76M 4,693.93M 4,386.17M 5,070.54M
Operating income 682.06M 901.04M 1,275.49M 533.13M 530.58M
Income before tax 692.96M 806.65M 1,177.85M 495.49M 484.61M
Net income 467.77M 571.58M 1,119.94M 397.13M 426.74M
EBITDA 918.30M 1,143.08M 1,585.44M 875.39M 872.28M
Diluted EPS 1.63 1.99 3.90 1.38 1.48
Dividends Per Share 1.35 1.35 1.47 1.50 1.42
Total Assets 9,863.94M 9,680.80M 9,838.72M 9,864.33M 10,210.62M
Total liabilities 4,089.64M 3,790.38M 3,330.17M 3,276.62M 3,854.01M
Total equity 5,581.39M 5,674.84M 6,281.57M 6,363.64M 6,169.48M
Operating cash flow 1,350.22M 935.24M 945.33M 696.34M 1,046.42M

Valuation Measures

Mar 2022
Operating margin7.88%
Profit margin6.34%

Key executives

  • Chief Executive Officer & Representative Director: Haruo Naito
  • COO, Representative Executive Officer & Head-China: Yasushi Okada
  • Chief Financial Officer & Chief IR Officer: Tatsuyuki Yasuno
  • Chief Medical & Chief Clinical Officer-Neurology: Lynn D. Kramer
  • Executive Officer & Head-Global IT Headquarters: Keisuke Naito


  • Wellington Management Co. LLP (8.0%)
  • Nomura Asset Management Co., Ltd. (6.0%)
  • Government of Japan (5.0%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
  • Nippon Life Insurance Co. (3.2%)
  • Eisai Co., Ltd. (3.2%)
  • Asset Management One Co., Ltd. (3.0%)
  • Nikko Asset Management Co., Ltd. (2.9%)
  • Daiwa Asset Management Co. Ltd. (2.8%)
  • The Vanguard Group, Inc. (2.2%)

Contact Details

  • Website:
  • Address: 4-6-10 Koishikawa, Bunkyo-Ku, Tokyo, 112-8088, Japan
  • Phone: +81.3.3817.3700

Related Companies

  • Eisai Innovation, Inc.
  • Eisai Europe Ltd.
  • Eisai LLC
  • Eisai Machinery China Co. Ltd.
  • Eisai Laboratorios S de RL de CV
  • Eisai GesmbH
  • Eisai Farmaceutica, Unipessoal Lda.
  • Eisai Clinical Research Singapore Pte Ltd.
  • Eisai Ltd. (Canada)
  • Eisai SA/NV
  • Eisai (Malaysia) Sdn. Bhd.
  • Eisai (Thailand) Marketing Co., Ltd.
  • Eisai AB
  • Eisai Pharma AG
  • Eisai (Singapore) Pte Ltd.
  • Eisai Co. Ltd. /Misato Factory/
  • Eisai Board Incentive Plan
  • Eisai Corporate Pension Fund
  • Eisai Pension Fund
  • Eisai China, Inc.
  • H3 Biomedicine, Inc.
  • Eisai R&D Management Co., Ltd.
  • Herusu Co., Ltd.
  • Gakuen Shoji Co., Ltd.
  • PT Eisai Indonesia
  • Eisai Taiwan, Inc.
  • Eisai (Hong Kong) Co., Ltd.
  • Eisai Australia Pty Ltd.
  • Eisai Pharmaceuticals India Pvt Ltd.
  • Eisai GmbH


  • JW Holdings Corporation
  • Ipsen SA
  • Ventyx Biosciences, Inc.
  • Denali Therapeutics Inc.
  • Immutep Ltd
  • JW Pharmaceutical Corporation
  • Morphic Holding, Inc.
  • Mirati Therapeutics Inc.
  • Exelixis, Inc.
  • Codiak BioSciences, Inc.
  • Blueprint Medicines Corp.
  • Arcutis Biotherapeutics Inc
  • Prometheus Biosciences, Inc
  • Aprea Therapeutics, Inc.
  • Verastem, Inc.
  • Cortexyme, Inc.
  • Ikena Oncology, Inc.
  • Iovance Biotherapeutics Inc
  • TCR2 Therapeutics, Inc.
  • Tyra Bioscience, Inc
  • Aeolus Pharmaceuticals, Inc.
  • Olema Pharmaceuticals, Inc.
  • AC Immune SA
  • Vivoryon Therapeutics N.V.
  • Xenon Pharmaceuticals Inc.
  • Prothena Corp. Plc
  • Vaxxinity Inc Class A
  • Aptinyx Inc
  • NeuroBo Pharmaceuticals, Inc.
  • Cyclerion Therapeutics,Inc.
Last Updated on 5 Jul, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more